Trial-Results center  
Clinical trial results database Feedback    Home

This trial is included in the following systematic reviews and meta-analyses:

heart failure - BNP guided management - all type of patients  


Related trials

PROTECT, 2009 - BNP-guided management vs control

BATTLESCARRED, 2009 - BNP-guided management vs control

TIME CHF, 2009 - BNP-guided management vs control

STARS-BNP, 2007 - BNP-guided management vs control

STARBRITE, 2007 - BNP-guided management vs control

Troughton, 2000 - BNP-guided management vs control

PRIMA, 0 - BNP-guided management vs control



See also:

  • All heart failure clinical trials
  • All clinical trials of BNP guided management
  • All clinical trials of BNP-guided management
    		•  

    STARS-BNP study, 2007

    Treatments

    Studied treatment BNP-guidance as a supplement to clinical judgment
    goal of decreasing BNP plasma levels <100 pg/ml
    Control treatment traditional approach
    medical treatment according to either current guidelines

    Patients

    Patients patients in NYHA functional class 2-3 with an LVEF <45%; optimally treated with angiotensin-converting enzyme inhibitors (ACEIs), beta-blockers, and diuretics by CHF specialists

    Method and design

    Randomized effectives 110 / 110 (studied vs. control)
    Design Parallel groups
    Blinding open
    Follow-up duration 6 mo
    Primary endpoint CHF-related death or hospital stay for CHF


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    death or hospitalization

    24 / 110
         52 / 110
         0,46 [0,31;0,69]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    death or hospitalization 24 / 110 (21,8%) 52 / 110 (47,3%) 0,46 [0,31;0,69] HF-related death or unplanned hospitalization   
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    death or hospitalization 21,82% 47,27% -254,5‰


    Reference(s)

    Trials register # NA
    • Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF, Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, Juillière Y. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study.. J Am Coll Cardiol 2007;49:1733-9
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend